Inulin‐Butyrate Nanogel for Modulation of Gut Microbiome, Intestinal Barrier, and Regulatory T‐Cells in Colitis
Small · 2026-05 · 22 (27)
DOI: 10.1002/smll.202513252 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, online erschienen am 19.03.2026. Verfasst von Nayoon Park und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Ewha Womans University, Seoul, South Korea. Hauptthemen laut MEDLINE: Colitis, Inulin, Butyrates, T-Lymphocytes, Regulatory. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Health & Welfare, Republic of Korea.
Abstract (Originalsprache)
Inflammatory bowel diseases (IBD) arise from a vicious cycle of intestinal barrier dysfunction, gut microbiome dysbiosis, and dysregulated immune responses. Current therapies predominantly suppress immunity but fail to address root causes or break this cycle. While inulin, a prebiotic, restores microbial diversity and enables colon‐targeted drug delivery, they lack specificity for inflamed tissue. On the other hand, even though butyrate, a microbial metabolite, is a potent enhancer of intestinal barrier integrity and anti‐inflammatory Treg cell differentiation, their clinical applications are limited by rapid systemic absorption, impractical dosing, and unpleasant odor. To address these limitations, we have developed an inulin‐butyrate conjugate‐based nanogel (IBN) which is capable of targeted modulation of gut microbiome, intestinal barrier, and immune systems in colitis. In dextran sodium sulfate (DSS)‐induced colitis mice, IBN specifically accumulates in the inflamed colon and released high amounts of butyrate via gut microbial enzymes (inulinase/esterase). The inulin shell improved the gut microbiome, while the released butyrate enhances intestinal barrier functions and promotes Treg differentiation, yielding robust therapeutic activity. Taken together, IBN addresses the multifactorial nature of IBD, offering a biocompatible, transformative strategy to disrupt the disease cycle and restore gut homeostasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Ewha Womans University, Seoul, South Korea.
- Gradutate Program in Innovative Biomaterials Convergence, Ewha Womans University, Seoul, South Korea.
- Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, South Korea.
- College of Pharmacy, Chung-Ang University, Seoul, South Korea.
ORCID-Profile: Yonghyun Lee
Förderung
- National Research Foundation of Korea
- Ministry of Health & Welfare, Republic of Korea
Zitieren
APA
Park, N., Lee, B., Jeon, H. J., Yeon Kim, J., Park, S., Kim, S. E., Lee, D. K., & Lee, Y. (2026). Inulin‐Butyrate Nanogel for Modulation of Gut Microbiome, Intestinal Barrier, and Regulatory T‐Cells in Colitis. Small, 22(27). https://doi.org/10.1002/smll.202513252
Vancouver
Park N, Lee B, Jeon HJ, Yeon Kim J, Park S, Kim SE, et al. Inulin‐Butyrate Nanogel for Modulation of Gut Microbiome, Intestinal Barrier, and Regulatory T‐Cells in Colitis. Small. 2026;22(27). doi:10.1002/smll.202513252
BibTeX
@article{Park2026,
author = {Park, Nayoon and Lee, Bom and Jeon, Hyeon-Jeong and Yeon Kim, Ji and Park, Suyeon and Kim, Seong-Eun and Lee, Dong-Kyu and Lee, Yonghyun},
title = {Inulin‐Butyrate Nanogel for Modulation of Gut Microbiome, Intestinal Barrier, and Regulatory T‐Cells in Colitis},
journal = {Small},
year = {2026},
volume = {22},
number = {27},
doi = {10.1002/smll.202513252}
}
EUVIMED